Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma
Megadott ok: Study on clinical hold by FDA
Key facts
- Where
- Aurora, Edmond, El Paso, Grants Pass, Greenfield, McKinney, Miami, Miami Lakes, San Jose, Stockton, Tampa és Westminster, Egyesült ÁllamokSee the 13 sites
- Phase
- 2. fázis
Where in Egyesült Államok
- Allianz Research Institute COAurora, Egyesült ÁllamokNo longer taking part
- OK Clinical Research, LLCEdmond, Egyesült ÁllamokNo longer taking part
- Western Sky Medical ResearchEl Paso, Egyesült ÁllamokNo longer taking part
- Velocity Clinical Research, Grants PassGrants Pass, Egyesült ÁllamokNo longer taking part
- Allergy, Asthma & Sinus Ceneter SCGreenfield, Egyesült ÁllamokNo longer taking part
- Metroplex Pulmonary & Sleep CenterMcKinney, Egyesült ÁllamokNo longer taking part
- Coral Research Clinical CorpMiami, Egyesült ÁllamokNo longer taking part
- Sonce Medical ResearchMiami, Egyesült ÁllamokNo longer taking part
- San Marcos Research ClinicMiami Lakes, Egyesült ÁllamokNo longer taking part
- Allergy and Asthma Associates of Santa Clara Valley Research CenterSan Jose, Egyesült ÁllamokNo longer taking part
- Bensch Clinical Research LLCStockton, Egyesült ÁllamokNo longer taking part
- Clinical Research Trials of FloridaTampa, Egyesült ÁllamokNo longer taking part
- Allianz Research InstituteWestminster, Egyesült ÁllamokNo longer taking part
Trial details
- Who runs it
- RAPT Therapeutics, Inc., a member of the GSK plc group of companies
- Trial code
- NCT05935332
- Record updated
- 2026. március 23.
- Original description
Randomized, multi-center, double-blind, placebo-controlled, parallel group, proof of-concept study with RPT193 in subjects with T2-high, moderate-to-severe asthma who are partially controlled on medium or high doses of inhaled corticosteroids (ICS) in combination with long-acting beta 2 agonist (LABA).Read full original descriptionShow less
A Phase 2 Study to Evaluate the Efficacy and Safety of RPT193 in Adults With Moderate-to-severe T2-high Asthma Who Are Partially Controlled on Inhaled Corticosteroid and Long-acting Beta 2 Agonist Therapy
Randomized, multi-center, double-blind, placebo-controlled, parallel group, proof of-concept study with RPT193 in subjects with T2-high, moderate-to-severe asthma who are partially controlled on medium or high doses of inhaled corticosteroids (ICS) in combination with long-acting beta 2 agonist (LABA).
Inclusion: Physician diagnosis of asthma for ≥6 months; Pre-bronchodilator FEV1 of >40% and <80%; History of treatment with corticosteroid or hospitalization for worsening asthma; Medium- or high-dose inhaled corticosteroid use.
Exclusion: Requires systemic oral or IV corticosteroids in the month prior to screening; History of smoking/vaping; History of severe COVID; Serious and/or uncontrolled pulmonary, cardiac, immune system conditions.